Table 5.
Sclerostin Versus CVD Disease Outcomes (LURIC/ALSPAC)
LURIC (N = 2054) | ||||
---|---|---|---|---|
Exposure | Outcome | Model | β (95% CI) | p |
Sclerostin | Friesinger score | 1 | 0.14 (0.09, 0.18) | <0.001 |
Sclerostin | Friesinger score | 2 | 0.05 (0.01, 0.09) | 0.018 |
Sclerostin | Friesinger score | 3 | 0.03 (−0.02, 0.07) | 0.252 |
HR (95% CI) | p | |||
---|---|---|---|---|
Sclerostin | Death from cardiac cause | 1 | 1.21 (1.14, 1.28) | <0.001 |
Sclerostin | Death from cardiac cause | 2 | 1.13 (1.03, 1.23) | 0.007 |
Sclerostin | Death from cardiac cause | 3 | 1.03 (0.93, 1.15) | 0.557 |
OR (95% CI) | p | |||
---|---|---|---|---|
Sclerostin | Coronary artery stenosis a | 1 | 1.47 (1.29, 1.67) | <0.001 |
Sclerostin | Coronary artery stenosis a | 2 | 1.16 (1.02, 1.32) | 0.026 |
Sclerostin | Coronary artery stenosis a | 3 | 1.09 (0.96, 1.24) | 0.189 |
ALSPAC (N = 3015) | ||||
---|---|---|---|---|
Outcome | β (95% CI) | |||
Sclerostin | cIMT | 1 | 0.06 (0.03, 0.10) | 0.001 |
Sclerostin | cIMT | 2 | 0.02 (−0.02, 0.05) | 0.409 |
Sclerostin | cIMT | 3 | 0.01 (−0.02, 0.05) | 0.550 |
Sclerostin | Av. distensibility | 1 | −0.02 (−0.05, 0.02) | 0.328 |
Sclerostin | Av. distensibility | 2 | 0.02 (−0.01, 0.06) | 0.183 |
Sclerostin | Av. distensibility | 3 | 0.03 (−0.01, 0.07) | 0.106 |
CVD = cardiovascular disease; LURIC = Ludwigshafen Risk and Cardiovascular Health; ALSPAC = Avon Longitudinal Study of Parents and Children; CI = confidence interval; HR = hazard ratio; OR = odds ratio; cIMT = carotid intima media thickness.
Table shows results of linear/logistic/Cox proportional hazards regression analysis. Results are SD change in outcome/odds/HR of outcome per SD increase in sclerostin, 95% CI, and p value. Model 1: unadjusted; model 2: adjusted for age and ethic group (ALSPAC) and sex (LURIC), body mass index, smoking, and social deprivation; model 3: model 2 plus LDL and HDL cholesterol, log triglycerides, diabetes, hypertension, estimated glomerular filtration rate, and apolipoprotein A‐I.
Based on n = 2023.